Public Attitudes toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota.

Public Attitudes toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota.
复制标题

DOI:
10.3390/jpm12101615
复制
发表时间:
2022-09-30
影响因子:
--
通讯作者:
Bishop JR
Bishop JR
中科院分区:
医学4区
文献类型:
--
作者:
Zhang L;Jacobson PA;Johnson ANK;Gregornik DB;Johnson SG;McCarty CA;Bishop JR

文献摘要

参考文献

被引文献

相似文献

The clinical adoption and implementation of pharmacogenomics (PGx) beyond academic medical centers remains slow, restricting the general population from benefitting from this important component of personalized medicine. As an initial step in the statewide initiative of PGx implementation in Minnesota, we engaged community members and assessed attitudes towards PGx testing and acceptability of establishing a secure statewide PGx database for clinical and research use among Minnesota residents. Data was collected from 808 adult attendees at the 2021 Minnesota State Fair through an electronic survey. Eighty-four percent of respondents felt comfortable getting a PGx test for clinical care. Most respondents trusted health professionals (78.2%) and researchers (73.0%) to keep their PGx data private. The majority expressed their support and interest in participating in a statewide PGx database for clinical and research use (64–72%). Higher acceptability of the statewide PGx database was associated with younger age, higher education, higher health literacy, having health insurance, and prior genetic testing. The study sample representing Minnesota residents expressed high acceptability of receiving PGx testing and willingness to participate in PGx data sharing for clinical and research use. Community support and engagement are needed to advance PGx implementation and research on the state scale.
DOI: 10.1146/annurev-pharmtox-010814-124835
发表时间: 2015
影响因子: 12.5
作者:
Dunnenberger HM;Crews KR;Hoffman JM;Caudle KE;Broeckel U;Howard SC;Hunkler RJ;Klein TE;Evans WE;Relling MV
通讯作者: Relling MV
DOI: 10.3389/fphar.2020.595219
发表时间: 2020
影响因子: 5.6
作者:
Abdullah-Koolmees H;van Keulen AM;Nijenhuis M;Deneer VHM
通讯作者: Deneer VHM
DOI: 10.1038/tpj.2016.72
发表时间: 2017-01
期刊: The pharmacogenomics journal
影响因子: --
作者:
Bielinski SJ;St Sauver JL;Olson JE;Wieland ML;Vitek CR;Bell EJ;Mc Gree ME;Jacobson DJ;McCormick JB;Takahashi PY;Black JL;Caraballo PJ;Sharp RR;Beebe TJ;Weinshilboum RM;Wang L;Roger VL
通讯作者: Roger VL
DOI: 10.1080/10810730.2016.1144661
发表时间: 2016-03-28
影响因子: 4.4
作者:
Kaphingst, Kimberly A.;Blanchard, Melvin;Goodman, Melody S.
通讯作者: Goodman, Melody S.
DOI: 10.2217/pgs-2021-0058
发表时间: 2021-06-17
期刊: PHARMACOGENOMICS
影响因子: 2.1
作者:
Bishop, Jeffrey R.;Huang, R. Stephanie;Jacobson, Pamala A.
通讯作者: Jacobson, Pamala A.